Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study.

DeFronzo, Ralph A; Fleck, Penny R; Wilson, Craig A; Mekki, Qais

DeFronzo, Ralph A; Fleck, Penny R; Wilson, Craig A; Mekki, Qais.

Affiliation

DeFronzo RA; University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA. albarado@uthscsa.edu

Diabetes Care ; 31(12): 2315-7, 2008 Dec.

Article in En | MEDLINE | ID: mdl-18809631

Subject(s)

Diabetes Mellitus, Type 2/drug therapy; Dipeptidyl-Peptidase IV Inhibitors/therapeutic use; Piperidines/therapeutic use; Uracil/analogs & derivatives; Diabetes Mellitus, Type 2/blood; Double-Blind Method; Female; Humans; Hypoglycemic Agents/therapeutic use; Male; Middle Aged; Uracil/therapeutic use

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperidines / Uracil / Diabetes Mellitus, Type 2 / Dipeptidyl-Peptidase IV Inhibitors Type of study: Clinical_trials Limits: Female / Humans / Male / Middle aged Language: En Journal: Diabetes Care Year: 2008 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google